Aarti Drugs Ltd., incorporated in the year 1984, is a Small Cap company (having a market cap of Rs 6174.97 Crore) operating in Pharmaceuticals sector.
Promoters held 60.2 per cent stake in the company as of Sept 30, 2020, while FIIs held 2.2 per cent, DIIs 1.9 per cent and public and others 35.8 per cent.
Centrum Broking has given a buy rating to Aarti Drugs with a target price of Rs 825. The share price moved down by 2.43 per cent from its previous close of Rs 675.80. The stock’s last traded price is Rs 659.35. Aarti Drugs Ltd., incorporated in the year 1984, is a Small Cap company (having a market cap of Rs 6174.97 Crore) operating in Pharmaceuticals sector.
Financials For the quarter ended 30-09-2020, the company reported a Consolidated sales of Rs 578.11 Crore, up 6.14 % from last quarter Sales of Rs 544.67 Crore and up 21.07 % from last year same quarter Sales of Rs 477.50 Crore Company reported net profit after tax of Rs 75.27 Crore in latest quarter.
Investment Rationale ADL continuing with strong volume growth and sustaining elevated EBITDA margins as the brokerage has further upgraded earnings by 8%/33%, for FY21E/FY22E, respectively. It maintains Buy rating with 18xFY22E (aligning with Lead multiple) with new target price of Rs 825. Promoter/FII Holdings Promoters held 60.2 per cent stake in the company as of Sept 30, 2020, while FIIs held 2.2 per cent, DIIs 1.9 per cent and public and others 35.8 per cent.
Get Unlimited Access to The Economic Times
